FLT3 and acute myeloid leukemia: To assess usefulness of combining splicing changes and mutations to predict drug response, we prioritize FLT3-ITD and Sorafenib and NPM1 and Venetoclax due to reliable mutation calls and their prominent role in AML clinical diagnosis.